Company intelligence / Profile preview
Checkpoint Therapeutics, Inc.
Waltham, Massachusetts, United Statescheckpointtx.com ↗
- Ownership
- Public · CKPT
- Employees
- ~24
- Development stage
- Other
01
Overview
Checkpoint Therapeutics received FDA approval for UNLOXCYT (cosibelimab-ipdl) in December 2024 for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. In clinical trials, Unloxcyt showed a 47% response rate in metastatic CSCC and 48% in locally advanced disease.
- Therapeutic areas
- Oncology
- Modalities
- AntibodiesSmall molecules
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
GC Cell (Immuncell-LC)
Beyond the preview
Go deeper on Checkpoint Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Checkpoint Therapeutics, Inc..